Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners » 07:04
01/12/22
01/12
07:04
01/12/22
07:04
OPGN

OpGen

/

+

, NVS

Novartis

$89.88 /

-0.185 (-0.21%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor lowered the firm's price target on OpGen (OPGN) to $3 from $4.35 due "entirely" to a reduction in his valuation multiple to reflect the recent re-rating of small-cap diagnostic firm valuation multiples. However, he keeps a Buy rating on the shares, stating that he is encouraged by the company's clinical and regulatory progress as well as the validation received by the extension of the Ares and Sandoz (NVS) collaboration agreement into 2025.

ShowHide Related Items >><<
OPGN OpGen
/

+

NVS Novartis
$89.88 /

-0.185 (-0.21%)

OPGN OpGen
/

+

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
NVS Novartis
$89.88 /

-0.185 (-0.21%)

01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
12/14/21 Redburn
Novartis downgraded to Neutral from Buy at Redburn
OPGN OpGen
/

+

NVS Novartis
$89.88 /

-0.185 (-0.21%)

NVS Novartis
$89.88 /

-0.185 (-0.21%)

OPGN OpGen
/

+

NVS Novartis
$89.88 /

-0.185 (-0.21%)

NVS Novartis
$89.88 /

-0.185 (-0.21%)

Earnings
OpGen sees Q4 revenue $1.4M, two estimate $900,000 » 07:41
01/10/22
01/10
07:41
01/10/22
07:41
OPGN

OpGen

/

+

Oliver Schacht, President…

Oliver Schacht, President & CEO of OpGen, commented, "We are pleased with our fourth quarter and full year 2021 preliminary results and are off to a solid start in 2022. With our much improved cash position and existing network of global partnerships, we are convinced that across our portfolio of products and services we have the potential to see them contribute significantly to our growth in the year ahead. I am especially excited about upcoming key milestones such as Chinese clinical study data and pending NMPA approval decision, our Unyvero UTI clinical trial and anticipated FDA submission, the Unyvero A30 platform development and partnering milestones and Ares Genetics' commercial expansion in Europe as well as here in the U.S. with the recent addition of our SVP Corporate Development and Operations for Ares." He added: "We continue our dialog with the European Investment Bank regarding the various options to structure a repayment - either in cash or in equity or a combination thereof - of the loan outstanding. The first tranche matures and is due for repayment in April 2022."

ShowHide Related Items >><<
OPGN OpGen
/

+

OPGN OpGen
/

+

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
OPGN OpGen
/

+

OPGN OpGen
/

+

Earnings
OpGen sees FY21 revenue $4.3M, consensus $3.8M » 07:40
01/10/22
01/10
07:40
01/10/22
07:40
OPGN

OpGen

/

+

OpGen's cash…

OpGen's cash position as of December 31, 2021 was approximately $36.1M, a significant increase from $13.3M as of December 31, 2020.

ShowHide Related Items >><<
OPGN OpGen
/

+

OPGN OpGen
/

+

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
OPGN OpGen
/

+

OPGN OpGen
/

+

Over a month ago
Hot Stocks
OpGen subsidiary Ares Genetics announces expansion of ARESdb » 07:42
12/14/21
12/14
07:42
12/14/21
07:42
OPGN

OpGen

$1.27 /

-0.035 (-2.69%)

OpGen announced that its…

OpGen announced that its subsidiary, Ares Genetics, has successfully completed Phase 1 of its collaboration with a U.S. CRO and reference lab, originally announced in August. During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens. Ares Genetics has developed ARESdb, a leading database on antimicrobial resistance, AMR. ARESdb not only comprehensively collects known genetic markers for AMR, but also harbors more than 78,000 datasets essential for the development and training of predictive models. This is up by over 40% from around 55,000 datasets a year ago. OpGen CEO Oliver Schacht added: "Ares will also be applying its next generation sequencing and AI-powered bioinformatics capabilities to analyze the clinical patient samples collected during OpGen's Unyvero UTI clinical trial in the U.S. which will further expand the unique and proprietary contents of ARESdb. We expect Ares to become one of the key drivers of growth for OpGen in the coming years as we also seek to expand the commercial footprint and activities of Ares in the U.S. beginning in January of 2022."

ShowHide Related Items >><<
OPGN OpGen
$1.27 /

-0.035 (-2.69%)

OPGN OpGen
$1.27 /

-0.035 (-2.69%)

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
OPGN OpGen
$1.27 /

-0.035 (-2.69%)

OPGN OpGen
$1.27 /

-0.035 (-2.69%)

Hot Stocks
OpGen subsidiary Ares Genetics announces database access transaction » 08:48
11/30/21
11/30
08:48
11/30/21
08:48
OPGN

OpGen

$1.56 /

-0.02 (-1.27%)

OpGen announced that its…

OpGen announced that its subsidiary Ares Genetics entered into a strategic database access transaction with an unnamed global corporation and leader in microbiology and infectious disease diagnostics. Under the terms of the agreement, the unnamed IVD corporation gains immediate, permanent, unrestricted and non-exclusive access to a small subset constituting approximately 1.1% of the total current database content of Ares Genetics' proprietary ARESdb. Under the terms of the agreement, Ares Genetics grants the global IVD corporation access to an ARESdb subset of associated genotype and AMR phenotype data for a narrowly defined and non-disclosed group of pathogens implicated in a widespread type of infections resistant to treatment. For the subset, corresponding to ~1.1% of total ARESdb content, the unnamed IVD corporation pays Ares Genetics an undisclosed one-time data generation, data transfer and data access fee. Oliver Schacht, CEO of OpGen added, "In just a couple of quarters Arne Materna has transformed Ares Genetics from a research stage technology business into a commercially driven part of OpGen. This transaction is yet another example of the growing commercial traction and adds this global leader to the list of collaborations and deals that Ares has with Sandoz, QIAGEN and others. Looking at the value proposition it is clear that the implied value of ARESdb is far greater than the intangible asset value carried on our balance sheet for Ares Genetics and this may help crystallize the promise of future value creation that we expect to deliver to be communicated and appreciated in the eyes of the markets."

ShowHide Related Items >><<
OPGN OpGen
$1.56 /

-0.02 (-1.27%)

OPGN OpGen
$1.56 /

-0.02 (-1.27%)

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
OPGN OpGen
$1.56 /

-0.02 (-1.27%)

OPGN OpGen
$1.56 /

-0.02 (-1.27%)

Hot Stocks
OpGen appoints Albert Weber as CFO » 08:06
11/04/21
11/04
08:06
11/04/21
08:06
OPGN

OpGen

$1.81 /

+0.015 (+0.84%)

OpGen announced the…

OpGen announced the appointment of Albert Weber as OpGen's new Chief Financial Officer and Managing Director of OpGen's subsidiary Curetis GmbH effective January 1, 2022. Mr. Weber is a corporate finance executive who brings more than 30 years of professional experience in accounting, controlling and corporate finance roles. During the last 21 years, he served in several roles for Epigenomics AG, a molecular diagnostics company listed on the Frankfurt Stock Exchange, with operations in the United States and Germany. Since 2018, Mr. Weber served as Executive Officer and Executive Board member and EVP Finance. Mr. Weber will initially be based in Germany and work primarily out of the Company's Curetis GmbH office in Holzgerlingen near Stuttgart, but expects to spend a significant amount of time at the U.S. headquarters in 2022 and beyond as he will oversee and manage the global finance teams in their entirety. Inducement Grant under NASDAQ Listing Rule 5635(c)(4) In connection with the appointment of Mr. Weber, OpGen granted Mr. Weber an inducement grant of stock options to purchase an aggregate of 210,00 shares of OpGen's common stock with a grant date of January 3, 2022. The equity award was granted pursuant to Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a component of Mr. Weber's employment compensation and was granted as an inducement material to his acceptance of employment with OpGen. The options will have an exercise price equal to the closing price of OpGen's common stock as reported on Nasdaq on January 3, 2022, the first trading day after Mr. Weber's start date. The option award will vest over a four-year period with 25% vesting on the first anniversary of the date of grant and in equal quarterly installments on each quarterly anniversary thereafter. The award is subject to Mr. Weber's continued service with OpGen through the applicable vesting dates.

ShowHide Related Items >><<
OPGN OpGen
$1.81 /

+0.015 (+0.84%)

OPGN OpGen
$1.81 /

+0.015 (+0.84%)

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
11/13/20 Alliance Global Partners
OpGen price target raised to $5.65 from $5.00 at Alliance Global Partners
OPGN OpGen
$1.81 /

+0.015 (+0.84%)

OPGN OpGen
$1.81 /

+0.015 (+0.84%)

Hot Stocks
OpGen announces special meeting of stockholders » 08:02
11/04/21
11/04
08:02
11/04/21
08:02
OPGN

OpGen

$1.81 /

+0.015 (+0.84%)

OpGen announced it has…

OpGen announced it has scheduled a Special Meeting of stockholders for December 8, 2021 at 10:00 a.m., Eastern time, to approve its proposed increase of the number of authorized shares of common stock from 50 million to 100 million and to reduce the stockholder approval requirement for changes to the Company's Amended and Restated Certificate of Incorporation, as amended, to a majority of the outstanding shares entitled to vote. The proposal to increase the Company's authorized shares of common stock and reduce the stockholder approval requirement is set forth in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on October 29, 2021.

ShowHide Related Items >><<
OPGN OpGen
$1.81 /

+0.015 (+0.84%)

OPGN OpGen
$1.81 /

+0.015 (+0.84%)

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
11/13/20 Alliance Global Partners
OpGen price target raised to $5.65 from $5.00 at Alliance Global Partners
OPGN OpGen
$1.81 /

+0.015 (+0.84%)

OPGN OpGen
$1.81 /

+0.015 (+0.84%)

Over a quarter ago
Hot Stocks
OpGen subsidiary Ares Genetics launches AREScloud » 07:46
10/21/21
10/21
07:46
10/21/21
07:46
OPGN

OpGen

$1.94 /

-0.05 (-2.51%)

OpGen announced that its…

OpGen announced that its subsidiary Ares Genetics has commercially launched its AREScloud web application. "The advantage of whole genome sequencing over other molecular tests such as PCR resides in the technique's potential to provide in a single assay sensitive and precise information on pathogen identity along with information on AMR and virulence," says Dr. Arne Materna, CEO of Ares Genetics. "The challenge of many microbiology laboratories resides in converting WGS-derived complex genome data into actionable information on pathogen identity and AMR, along with treatment options and transmission potential." AREScloud fully automates data processing - from raw sequence data to report - and offers insights into epidemiologically and etiologically relevant information including pathogen identity, genotype, virulence, plasmids, and AMR. In addition to generating individual sample reports, the AREScloud version that has now been commercially released for the first time introduces unique features for comparative and outbreak analysis.

ShowHide Related Items >><<
OPGN OpGen
$1.94 /

-0.05 (-2.51%)

OPGN OpGen
$1.94 /

-0.05 (-2.51%)

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
11/13/20 Alliance Global Partners
OpGen price target raised to $5.65 from $5.00 at Alliance Global Partners
OPGN OpGen
$1.94 /

-0.05 (-2.51%)

OPGN OpGen
$1.94 /

-0.05 (-2.51%)

Syndicate
OpGen raises $15M ion a registered direct offering » 08:03
10/14/21
10/14
08:03
10/14/21
08:03
OPGN

OpGen

$2.07 /

-0.105 (-4.84%)

OpGen announced that it…

OpGen announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 150,000 shares of convertible preferred stock and warrants to purchase up to an aggregate of 7,500,000 shares of common stock for gross proceeds of $15 million in a registered direct offering. The shares of preferred stock will have a stated value of $100 per share and are convertible into an aggregate of 7,500,000 shares of common stock at a conversion price of $2.00 per share at any time after the Company has received shareholder approval to increase the number of authorized shares of common stock of the Company. The warrants have an exercise price of $2.05 per share, will become exercisable on the later of the date of shareholder approval and six months following the date of issuance, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about October 18, 2021, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

ShowHide Related Items >><<
OPGN OpGen
$2.07 /

-0.105 (-4.84%)

OPGN OpGen
$2.07 /

-0.105 (-4.84%)

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
11/13/20 Alliance Global Partners
OpGen price target raised to $5.65 from $5.00 at Alliance Global Partners
OPGN OpGen
$2.07 /

-0.105 (-4.84%)

OPGN OpGen
$2.07 /

-0.105 (-4.84%)

On The Fly
Wall Street in Fives - Must Read Lists for Monday » 16:12
10/04/21
10/04
16:12
10/04/21
16:12
TSLA

Tesla

$780.91 /

+6.505 (+0.84%)

, QCOM

Qualcomm

$126.76 /

-1.91 (-1.48%)

, VNE

Veoneer

$36.15 /

+1.64 (+4.75%)

, SLF

Sun Life Financial

$52.98 /

+1.52 (+2.95%)

, GM

General Motors

$53.97 /

+0.84 (+1.58%)

, FB

Facebook; also tag MVRS

$325.94 /

-16.805 (-4.90%)

, DD

DuPont

$70.08 /

+0.93 (+1.34%)

, MMM

3M

$176.14 /

-0.35 (-0.20%)

, WISH

ContextLogic

$4.84 /

-0.525 (-9.79%)

, ASTR

Astra

$7.78 /

-0.685 (-8.10%)

, LUV

Southwest

$55.02 /

+0.66 (+1.21%)

, GH

Guardant Health

$105.99 /

-1.54 (-1.43%)

, NEO

NeoGenomics

$43.22 /

-5.28 (-10.89%)

, AAPL

Apple

$138.99 /

-3.43 (-2.41%)

, TEVA

Teva

$9.61 /

-0.085 (-0.88%)

, BHP

BHP Group

$53.39 /

-0.14 (-0.26%)

, IVPAF

Ivanhoe Mines

$6.95 /

+0.54017 (+8.43%)

, BUD

AB InBev

$56.53 /

-0.055 (-0.10%)

, XENE

Xenon Pharmaceuticals

$31.75 /

+16.1 (+102.88%)

, TGP

Teekay LNG

$17.17 /

+1.43 (+9.09%)

, BTU

Peabody Energy

$17.00 /

+1.37 (+8.77%)

, AMPY

Amplify Energy

$3.21 /

-2.545 (-44.22%)

, TTD

Trade Desk

$65.99 /

-4.42 (-6.28%)

, PERI

Perion Network

$18.95 /

+0.99 (+5.51%)

, OPGN

OpGen

$2.92 /

+0.155 (+5.62%)

, JELD

Jeld-Wen

$24.89 /

-0.96 (-3.71%)

, ACC

American Campus

$50.89 /

+1.6 (+3.25%)

, KRT

Karat Packaging

$20.45 /

-0.48 (-2.29%)

Get caught up quickly on…

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$31.75 /

+16.1 (+102.88%)

WISH ContextLogic
$4.84 /

-0.525 (-9.79%)

VNE Veoneer
$36.15 /

+1.64 (+4.75%)

TTD Trade Desk
$65.99 /

-4.42 (-6.28%)

TSLA Tesla
$780.91 /

+6.505 (+0.84%)

TGP Teekay LNG
$17.17 /

+1.43 (+9.09%)

TEVA Teva
$9.61 /

-0.085 (-0.88%)

SLF Sun Life Financial
$52.98 /

+1.52 (+2.95%)

QCOM Qualcomm
$126.76 /

-1.91 (-1.48%)

PERI Perion Network
$18.95 /

+0.99 (+5.51%)

OPGN OpGen
$2.92 /

+0.155 (+5.62%)

NEO NeoGenomics
$43.22 /

-5.28 (-10.89%)

MMM 3M
$176.14 /

-0.35 (-0.20%)

LUV Southwest
$55.02 /

+0.66 (+1.21%)

KRT Karat Packaging
$20.45 /

-0.48 (-2.29%)

JELD Jeld-Wen
$24.89 /

-0.96 (-3.71%)

GM General Motors
$53.97 /

+0.84 (+1.58%)

GH Guardant Health
$105.99 /

-1.54 (-1.43%)

FB Facebook; also tag MVRS
$325.94 /

-16.805 (-4.90%)

DD DuPont
$70.08 /

+0.93 (+1.34%)

BUD AB InBev
$56.53 /

-0.055 (-0.10%)

BTU Peabody Energy
$17.00 /

+1.37 (+8.77%)

BHP BHP Group
$53.39 /

-0.14 (-0.26%)

ASTR Astra
$7.78 /

-0.685 (-8.10%)

AMPY Amplify Energy
$3.21 /

-2.545 (-44.22%)

ACC American Campus
$50.89 /

+1.6 (+3.25%)

AAPL Apple
$138.99 /

-3.43 (-2.41%)

TSLA Tesla
$780.91 /

+6.505 (+0.84%)

10/04/21 Wedbush
Tesla had 'eye popping' deliveries despite chip shortage, says Wedbush
10/04/21 Deutsche Bank
Tesla reported 'impressive' Q3 deliveries, says Deutsche Bank
10/04/21 RBC Capital
Tesla price target raised to $755 from $745 at RBC Capital
10/04/21 Bernstein
Current quarter profitability a 'key question' for Tesla, says Bernstein
QCOM Qualcomm
$126.76 /

-1.91 (-1.48%)

10/05/21 Jefferies
Veoneer takeover has positive read through to Aptiv, says Jefferies
10/05/21 KeyBanc
Apple seeing strong demand for iPhone 13, says KeyBanc
10/05/21 KeyBanc
Qualcomm price target lowered to $175 from $190 at KeyBanc
10/01/21
Fly Intel: Top five analyst initiations
VNE Veoneer
$36.15 /

+1.64 (+4.75%)

09/03/21 Danske Bank
Veoneer downgraded to Hold from Buy at Danske Bank
08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Credit Suisse
Veoneer upgraded to Neutral from Underperform at Credit Suisse
SLF Sun Life Financial
$52.98 /

+1.52 (+2.95%)

10/05/21 CIBC
Sun Life Financial upgraded to Outperformer from Neutral at CIBC
08/05/21 TD Securities
Sun Life Financial price target lowered to C$73 from C$75 at TD Securities
07/26/21 Canaccord
Sun Life Financial price target raised to C$74 from C$73 at Canaccord
07/12/21 Barclays
Sun Life Financial price target raised to C$62 from C$61 at Barclays
GM General Motors
$53.97 /

+0.84 (+1.58%)

10/01/21 Credit Suisse
GM investor day to highlight growth opportunities, says Credit Suisse
09/26/21 Goldman Sachs
General Motors price target lowered to $59 from $62 at Goldman Sachs
09/24/21 Citi
GM investor day could be 'significant positive catalyst,' says Citi
09/13/21 Barclays
General Motors price target lowered to $68 from $71 at Barclays
FB Facebook; also tag MVRS
$325.94 /

-16.805 (-4.90%)

10/05/21 DZ Bank
Facebook downgraded to Hold from Buy at DZ Bank
10/05/21 Piper Sandler
Snap remained favorite app among teens in Piper's semi-annual survey
09/30/21 RBC Capital
Facebook initiated with an Outperform at RBC Capital
DD DuPont
$70.08 /

+0.93 (+1.34%)

10/04/21
Fly Intel: Top five analyst upgrades
10/04/21 JPMorgan
JPMorgan's Tusa downgrades 3M on lack of progress, prefers DuPont
10/04/21 JPMorgan
DuPont upgraded with share weakness 'overdriven' at JPMorgan
10/04/21 JPMorgan
DuPont upgraded to Overweight from Neutral at JPMorgan
MMM 3M
$176.14 /

-0.35 (-0.20%)

10/04/21
Fly Intel: Top five analyst downgrades
10/04/21 Barclays
3M price target lowered to $182 from $185 at Barclays
10/04/21 JPMorgan
3M downgraded to Neutral from Overweight at JPMorgan
WISH ContextLogic
$4.84 /

-0.525 (-9.79%)

10/04/21 Oppenheimer
ContextLogic downgraded to Underperform from Perform at Oppenheimer
10/04/21 Oppenheimer
ContextLogic downgraded to Underperform from Perform at Oppenheimer
08/23/21 Citi
ContextLogic price target lowered to $7.50 from $12 at Citi
ASTR Astra
$7.78 /

-0.685 (-8.10%)

10/04/21
Fly Intel: Top five analyst initiations
10/04/21 BofA
Astra initiated with an Underperform at BofA
07/27/21 Deutsche Bank
Astra initiated with a Buy at Deutsche Bank
LUV Southwest
$55.02 /

+0.66 (+1.21%)

10/04/21 Barclays
Southwest upgraded to Overweight from Equal Weight at Barclays
10/01/21
Fly Intel: Top five analyst upgrades
10/01/21 JPMorgan
Southwest upgraded to Overweight with $70 target at JPMorgan
GH Guardant Health
$105.99 /

-1.54 (-1.43%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
NEO NeoGenomics
$43.22 /

-5.28 (-10.89%)

08/26/21 Benchmark
NeoGenomics price target raised to $50 from $46 at Benchmark
06/03/21 Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
05/25/21 Truist
NeoGenomics price target lowered to $54 from $65 at Truist
02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
AAPL Apple
$138.99 /

-3.43 (-2.41%)

10/05/21 Piper Sandler
Piper teen survey shows clothing outranked food for first time since 2014
09/29/21 UBS
Initial demand for Apple's iPhone 13 suggests positive bias, says UBS
09/29/21 Evercore ISI
Evercore ISI sees upside to Apple's iPhone units and selling prices after survey
09/27/21 Credit Suisse
Apple iPhone 13 extended waits versus 12 cycle continue, says Credit Suisse
TEVA Teva
$9.61 /

-0.085 (-0.88%)

06/22/21 JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
05/04/21 UBS
Teva downgraded to Neutral from Buy at UBS
04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
BHP BHP Group
$53.39 /

-0.14 (-0.26%)

10/05/21 Deutsche Bank
BHP Group named short-term investment idea at Deutsche Bank
09/21/21 BofA
BHP Group downgraded to Neutral from Buy at BofA
09/20/21 Berenberg
BHP Group downgraded to Hold from Buy at Berenberg
09/14/21 Barclays
BHP Group downgraded to Equal Weight from Overweight at Barclays
IVPAF Ivanhoe Mines
$6.95 /

+0.54017 (+8.43%)

09/23/21 Citi
Ivanhoe Mines initiated with a Neutral at Citi
07/15/21 Canaccord
Ivanhoe Mines price target raised to C$10.50 from C$9.50 at Canaccord
07/12/21 Scotiabank
Ivanhoe Mines price target raised to C$11 from C$10 at Scotiabank
06/11/21 BMO Capital
Ivanhoe Mines price target raised to C$15 from C$10 at BMO Capital
BUD AB InBev
$56.53 /

-0.055 (-0.10%)

09/30/21
Fly Intel: Top five analyst downgrades
09/30/21 Argus
AB InBev downgraded to Hold from Buy at Argus
09/30/21 Argus
AB InBev downgraded to Hold from Buy at Argus
09/16/21
Fly Intel: Top five analyst upgrades
XENE Xenon Pharmaceuticals
$31.75 /

+16.1 (+102.88%)

10/04/21 Jefferies
Jefferies ups Xenon target to $50 after 'home run' epilepsy data
10/04/21 Guggenheim
Xenon Pharmaceuticals price target raised to $45 from $30 at Guggenheim
10/04/21 William Blair
Xenon's X-Tole data 'as good as it gets,' says William Blair
TGP Teekay LNG
$17.17 /

+1.43 (+9.09%)

10/05/21 Stifel
Teekay LNG downgraded to Hold from Buy at Stifel
10/04/21 JonesTrading
Teekay LNG downgraded to Hold from Buy at JonesTrading
10/04/21 B. Riley
Teekay LNG downgraded to Neutral from Buy at B. Riley
05/19/21 Deutsche Bank
Teekay LNG price target raised to $14 from $13 at Deutsche Bank
BTU Peabody Energy
$17.00 /

+1.37 (+8.77%)

10/04/21 B. Riley
Peabody Energy upgraded to Buy on rising price decks at B. Riley
10/04/21 B. Riley
Peabody Energy upgraded to Buy from Neutral at B. Riley
09/02/21 B. Riley
Peabody Energy price target raised to $15 from $11 at B. Riley
08/02/21 B. Riley
Peabody Energy price target raised to $11 from $7 at B. Riley
AMPY Amplify Energy
$3.21 /

-2.545 (-44.22%)

10/04/21 Roth Capital
Amplify Energy downgraded to Neutral from Buy at Roth Capital
12/15/20 Roth Capital
Amplify Energy upgraded to Buy on deleveraging opportunity at Roth Capital
12/15/20 Roth Capital
Amplify Energy upgraded to Buy from Neutral at Roth Capital
TTD Trade Desk
$65.99 /

-4.42 (-6.28%)

10/04/21 Vertical Group
Trade Desk downgraded to Neutral from Buy at Vertical Group
09/30/21 Cleveland Research
Trade Desk initiated with a Buy at Cleveland Research
09/22/21 Berenberg
Trade Desk assumed with a Buy at Berenberg
08/17/21 Citi
Trade Desk price target raised to $85 from $60 at Citi
PERI Perion Network
$18.95 /

+0.99 (+5.51%)

08/03/21 Lake Street
Perion Network price target raised at Lake Street after 'well-executed quarter'
07/01/21 Needham
Perion Network price target raised to $25 from $21 at Needham
06/28/21 Stifel
Perion Network price target raised to $21 at Stifel after preliminary Q2 report
06/28/21 Lake Street
Perion Network price target raised to $29 at Lake Street after pre-announcement
OPGN OpGen
$2.92 /

+0.155 (+5.62%)

05/14/21 Alliance Global Partners
OpGen selloff in shares a buying opportunity, says Alliance Global Partners
03/02/21 Alliance Global Partners
Alliance Global raises OpGen price target to $7, sees 'eventful 2021'
11/13/20 Alliance Global Partners
OpGen price target raised to $5.65 from $5.00 at Alliance Global Partners
JELD Jeld-Wen
$24.89 /

-0.96 (-3.71%)

07/15/21 Wells Fargo
Jeld-Wen initiated with an Overweight at Wells Fargo
05/27/21 Stifel
Jeld-Wen initiated with a Buy at Stifel
05/03/21 Barclays
Jeld-Wen price target raised to $34 from $31 at Barclays
03/17/21 Wolfe Research
Jeld-Wen initiated with an Outperform at Wolfe Research
ACC American Campus
$50.89 /

+1.6 (+3.25%)

09/23/21 Deutsche Bank
American Campus price target raised to $58 from $51 at Deutsche Bank
09/23/21 Goldman Sachs
American Campus initiated with a Buy at Goldman Sachs
05/28/21
Fly Intel: Top five analyst upgrades
05/28/21 Piper Sandler
American Campus upgraded to Overweight from Neutral at Piper Sandler
KRT Karat Packaging
$20.45 /

-0.48 (-2.29%)

05/18/21 William Blair
William Blair initiates 'well positioned' Karat Packaging with an Outperform
05/18/21 William Blair
Karat Packaging initiated with an Outperform at William Blair
05/11/21 DA Davidson
DA Davidson starts Karat Packaging with Buy on stable margin, growth potential
05/11/21 DA Davidson
Karat Packaging initiated with a Buy at DA Davidson
XENE Xenon Pharmaceuticals
$31.75 /

+16.1 (+102.88%)

WISH ContextLogic
$4.84 /

-0.525 (-9.79%)

VNE Veoneer
$36.15 /

+1.64 (+4.75%)

TTD Trade Desk
$65.99 /

-4.42 (-6.28%)

TSLA Tesla
$780.91 /

+6.505 (+0.84%)

TGP Teekay LNG
$17.17 /

+1.43 (+9.09%)

TEVA Teva
$9.61 /

-0.085 (-0.88%)

QCOM Qualcomm
$126.76 /

-1.91 (-1.48%)

PERI Perion Network
$18.95 /

+0.99 (+5.51%)

OPGN OpGen
$2.92 /

+0.155 (+5.62%)

MMM 3M
$176.14 /

-0.35 (-0.20%)

LUV Southwest
$55.02 /

+0.66 (+1.21%)

KRT Karat Packaging
$20.45 /

-0.48 (-2.29%)

JELD Jeld-Wen
$24.89 /

-0.96 (-3.71%)

GM General Motors
$53.97 /

+0.84 (+1.58%)

GH Guardant Health
$105.99 /

-1.54 (-1.43%)

FB Facebook; also tag MVRS
$325.94 /

-16.805 (-4.90%)

DD DuPont
$70.08 /

+0.93 (+1.34%)

BUD AB InBev
$56.53 /

-0.055 (-0.10%)

BTU Peabody Energy
$17.00 /

+1.37 (+8.77%)

ACC American Campus
$50.89 /

+1.6 (+3.25%)

AAPL Apple
$138.99 /

-3.43 (-2.41%)

  • 16
    Aug
  • 11
    May
  • 15
    Apr
  • 10
    Mar
  • 02
    Mar
  • 20
    Jan
  • 07
    Jan
  • 11
    Dec
  • 16
    Dec
  • 07
    Oct
WISH ContextLogic
$4.84 /

-0.525 (-9.79%)

VNE Veoneer
$36.15 /

+1.64 (+4.75%)

TSLA Tesla
$780.91 /

+6.505 (+0.84%)

TEVA Teva
$9.61 /

-0.085 (-0.88%)

QCOM Qualcomm
$126.76 /

-1.91 (-1.48%)

NEO NeoGenomics
$43.22 /

-5.28 (-10.89%)

MMM 3M
$176.14 /

-0.35 (-0.20%)

LUV Southwest
$55.02 /

+0.66 (+1.21%)

GM General Motors
$53.97 /

+0.84 (+1.58%)

GH Guardant Health
$105.99 /

-1.54 (-1.43%)

FB Facebook; also tag MVRS
$325.94 /

-16.805 (-4.90%)

DD DuPont
$70.08 /

+0.93 (+1.34%)

BUD AB InBev
$56.53 /

-0.055 (-0.10%)

BHP BHP Group
$53.39 /

-0.14 (-0.26%)

AMPY Amplify Energy
$3.21 /

-2.545 (-44.22%)

AAPL Apple
$138.99 /

-3.43 (-2.41%)

WISH ContextLogic
$4.84 /

-0.525 (-9.79%)

VNE Veoneer
$36.15 /

+1.64 (+4.75%)

TTD Trade Desk
$65.99 /

-4.42 (-6.28%)

TSLA Tesla
$780.91 /

+6.505 (+0.84%)

TEVA Teva
$9.61 /

-0.085 (-0.88%)

QCOM Qualcomm
$126.76 /

-1.91 (-1.48%)

PERI Perion Network
$18.95 /

+0.99 (+5.51%)

KRT Karat Packaging
$20.45 /

-0.48 (-2.29%)

GM General Motors
$53.97 /

+0.84 (+1.58%)

GH Guardant Health
$105.99 /

-1.54 (-1.43%)

FB Facebook; also tag MVRS
$325.94 /

-16.805 (-4.90%)

DD DuPont
$70.08 /

+0.93 (+1.34%)

BUD AB InBev
$56.53 /

-0.055 (-0.10%)

BTU Peabody Energy
$17.00 /

+1.37 (+8.77%)

BHP BHP Group
$53.39 /

-0.14 (-0.26%)

ASTR Astra
$7.78 /

-0.685 (-8.10%)

AAPL Apple
$138.99 /

-3.43 (-2.41%)

WISH ContextLogic
$4.84 /

-0.525 (-9.79%)

VNE Veoneer
$36.15 /

+1.64 (+4.75%)

TTD Trade Desk
$65.99 /

-4.42 (-6.28%)

TSLA Tesla
$780.91 /

+6.505 (+0.84%)

TGP Teekay LNG
$17.17 /

+1.43 (+9.09%)

TEVA Teva
$9.61 /

-0.085 (-0.88%)

QCOM Qualcomm
$126.76 /

-1.91 (-1.48%)

PERI Perion Network
$18.95 /

+0.99 (+5.51%)

MMM 3M
$176.14 /

-0.35 (-0.20%)

LUV Southwest
$55.02 /

+0.66 (+1.21%)

GM General Motors
$53.97 /

+0.84 (+1.58%)

FB Facebook; also tag MVRS
$325.94 /

-16.805 (-4.90%)

DD DuPont
$70.08 /

+0.93 (+1.34%)

BUD AB InBev
$56.53 /

-0.055 (-0.10%)

BTU Peabody Energy
$17.00 /

+1.37 (+8.77%)

BHP BHP Group
$53.39 /

-0.14 (-0.26%)

ASTR Astra
$7.78 /

-0.685 (-8.10%)

AAPL Apple
$138.99 /

-3.43 (-2.41%)

AAPL Apple
$138.99 /

-3.43 (-2.41%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.